1.778.600.0509
Advancing the Paradigm of Patient Care

Fighting
Antibiotic
Failure
ON TWO
FRONTS

Diagnostic

Novel assay provides earlier, faster diagnosis and targeted treatment of sepsis.

Therapeutic

Patented pharmaceutical peptide targets currently untreatable biofilm infections.

The crisis: Widespread and deadly*

49 million/year

cases of sepsis

11 million

sepsis deaths a year

100%

incidence of sepsis in COVID deaths

10 to 1000x

more resistant to most antibiotics

0

drugs approved for biofilms

65%

of all infections are biofilms

* Data on file

Investment Highlights

Large Addressable Global Markets

With NO efficient clinical solutions (unmet medical needs)

Novel Technologies

In the early diagnosis of sepsis and treatment of biofilm Infections

Extensive Intellectual Property

Portfolio of both Diagnostics and Therapeutics

Near-term Revenue Models

With multiple corporate partnership targets

Publicly-Listed

For enhanced shareholder liquidity

Experienced Management Team

With proven track records in med-tech and biopharma

Multibillion dollar opportunity

As sepsis and antibiotic-resistant infections continue to be a severe burden on the healthcare system, ASEP offers excellent investment potential, with a combined market of $179 billion, and robust growth.

$41.9B Global Antibiotic Market CAGR: 3%

Global MRSA Market*

$1.0B

CAGR: 4.4%

Global Device Infection Market

$2.0B

CAGR: 3.6%

Global CRS Market

$2.1B

CAGR: 7.4%

Global Ear Infection Market

$2.8B

CAGR: 5%

Global Bacterial Vaginosis

$4.5B

CAGR: 9%

Global Urinary Tract Infections

$9.5B

CAGR: 3.6%

Global Wound Care Market

$20B

CAGR: 4.1%

$1.0B Global Sepsis Dx CAGR: 8.5%

WEBINARS

Click the link below to view our archived webinars.

Contact

10 + 7 =

CSE: ASEP | OTCQB: SEPSF
This is default text for notification bar